Translational research is presented in a context of transformation in scientific findings, originating in basic, clinical research laboratories or epidemiological studies and providing new clinical tools, processes or applications(1). Translational research is aimed at improving patient care and promoting public health. To reach this goal, the intent is to build a bridge that connects the resea...

The term “translational research” first appeared on Pubmed in 1993 in a review by authors from the NIH calling for investigation of biomarkers for the early detection of cancer [1]. Since that publication, over 7,000 manuscripts on Pubmed use the search term “translational research.” Traditionally, translational research has been used to describe research discoveries initiated at the bench and ...

Approximately 200 worldwide researchers attended the fourth SENS Foundation’s conference at Queens’ College in Cambridge, UK, September 3–7, 2009. SENS conferences are distinguished from other biogerontological and aging research conferences by having more of an applied focus on antiaging therapies. The main subfields of aging research covered at SENS4 were intracellular and extracellular junk ...

Ongoing advances in the understanding of skin diseases have transformed dermatology as a specialty. 1 More detailed knowledge of the pathogenic mechanisms involved in the development of various skin disorders has given rise to new conceptual approaches and innovative forms of treatment, revolutionizing everyday dermatological practice. This shift would not have taken place without a constant fl...

Current treatment of malignant melanoma exemplifies not only the need for translational research but also many of the challenges of moving from bench to bedside. Melanoma remains unique among solid tumors in that its treatment primarily is surgical. Radiation is of limited benefit, and chemotherapy has been disappointing in both the adjuvant and metastatic settings. This leaves clinicians with ...

The major imperative of the pharmaceutical industry is to effectively translate insights gained from basic research into new medicines. This task is toughest for CNS disorders. Compared with non-CNS drugs, CNS drugs take longer to get to market and their attrition rate is greater. This is principally because of the complexity of the human brain (the cause of many brain disorders remains unknown...

We have seen, with some paternal pride, the first issue of EMBO Molecular Medicine (EMM). I am pleased to see the quality of the articles and the many lively sections of the journal; even more so because despite the excitement for this new initiative, I was slightly apprehensive about what seems to be a neverending proliferation of scientific journals. In the case of EMM, however, I feel that t...

We have seen, with some paternal pride, the first issue of EMBO Molecular Medicine (EMM). I am pleased to see the quality of the articles and the many lively sections of the journal; even more so because despite the excitement for this new initiative, I was slightly apprehensive about what seems to be a neverending proliferation of scientific journals. In the case of EMM, however, I feel that t...

Laboratory of Molecular and Cellular Aging, Institute of Biological Research and Biotechnology, National Hellenic Research Foundation; Faculty of Biology, Department of Cell Biology and Biophysics, University of Athens, Athens, Greece; Immunology Program, H. Lee Moffitt Cancer Center, Tampa, Florida; and Departments of Oncology and Pharmacology, Program in Cell Stress and Cancer Nanomedicine, L...